Skip to content

A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration in Adult Periodontitis Patients

A Novel Proline-rich Peptide Hydrogel for Periodontal Regeneration: a Multicenter Parallel-arm Randomized Clinical Trial

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07581613
Acronym
PERIHEAL
Enrollment
40
Registered
2026-05-12
Start date
2026-11-01
Completion date
2030-06-30
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrabony Periodontal Defects, Periodontal Disease

Keywords

periodontal regeneration, hydrogels

Brief summary

The goal of this clinical trial is to learn if a novel peptide-rich hydrogel works to achieve periodontal regeneration in adults. It will also learn about the safety of the hydrogel. The main questions it aims to answer are: * Does the novel peptide hydrogel achieve periodontal regeneration to a similar degree as another currently used therapy (hyaluronic acid)? * What medical problems, if any, do participants have when receiving the novel hydrogel treatment? Researchers will compare the novel peptide hydrogel to another commonly used hydrogel (hyaluronic acid) to see if the peptide hydrogel works to treat periodontal bone defects. Participants will: * Receive the novel hydorgel or hyaluronic acid when they undergo periodontal regenerative surgery * Visit the clinic at regular intervals for 1 year after the surgery for follow ups

Detailed description

The primary objective of this study (PICOS) is to compare, in adult periodontitis patients (P), the efficacy of a P-HA hydrogel (PeriHeal) (I) to that of a commercial HA hydrogel (hyaDENT BG) (C) for the regenerative treatment of intrabony defects based on CAL changes (O) after 6 and 12 months in a RCT (S). Additional objectives are to assess (a) changes in secondary clinical and radiographic outcomes, (b) patient-reported outcomes (PROs), and (c) molecular outcomes based on proteomic analysis of gingival crevicular fluid (GCF) (see details below). The null hypothesis (H0) is that there are no statistically significant differences between P-HA and HA hydrogels in terms of CAL after 6 and 12 months. The primary outcome is CAL change 6 and 12 months after regenerative surgery. Secondary outcomes measured 6 and 12 months after regenerative surgery include changes in: probing pocket depth (PPD), bleeding on probing (BoP), recession (REC), and MBL. Post-operative wound healing and patient-reported symptoms will be assessed 7 and 14 days after surgery. Patients' oral health-related quality of life (OHRQoL) will be assessed at baseline and 6 and 12 months after surgery. GCF collected at 7, 14 and 30 days after surgery will be analysed using mass spectrometry-based proteomics.

Interventions

BIOLOGICALHydrogel

A novel cross-linked HA hydrogel incorporating proline-rich peptides (PeriHeal, Corticalis AS, Oslo, Norway) has been developed to enhance periodontal wound healing and regeneration.

Sponsors

Siddharth Shanbhag
Lead SponsorOTHER
Universidad Complutense de Madrid
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults \>18 years with periodontitis (Stage III or IV) * Systemically healthy (ASA I or II) * Non-smokers or smoking \<10 cigarettes/day * Having undergone steps 1 (risk factor control, oral hygiene improvement including interdental hygiene) and 2 (subgingival instrumentation and biofilm control) of systematic periodontal therapy * Indication for step 3 periodontal therapy, i.e., sites with residual/persistent pockets (PPD \>5 mm and BoP or PPD \>6 mm) around single- or multi-rooted teeth with mobility \<grade II at re-evaluation 8-12 weeks after non-surgical instrumentation (Step 2). Further site-specific criteria include at least one site with a radiographic infrabony defect (2- or 3-walled) with a \>3 mm intrabony component, not associated with an open furcation, indicated for regenerative surgery * Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) ≤20% before surgery

Exclusion criteria

* Medical conditions contraindicating surgery * Pregnancy or lactation * Current use of systemic antibiotics * Smoking \>10 cigarettes/day * FMPS or FMBS \>20% * Mobility grade II or greater * Acute oral infections, active endo-perio lesions or active carious lesions on teeth associated with bone defects

Design outcomes

Primary

MeasureTime frameDescription
CAL change6 and 12 months after periodontal regenerative surgeryChanges in Clinical Attachment Level (CAL) of the treated teeth

Secondary

MeasureTime frameDescription
MBL change6 and 12 months after regenerative periodontal surgeryChanges in radiographic Marginal Bone Level (MBL)
Gingival Healing Index (GHI)7 and 14 days after periodontal regenerative surgeryGHI is used to assess the postsurgery conditions of the interdental papilla based on severity of wound dehiscence: score 3: no wound dehiscence and complete flap closure, score 2: minor wound dehiscence with loss of interdental soft tissue limited to the papillary tip; score 1: major wound dehiscence with incomplete flap closure.
Oral health related quality of life6 and 12 months after regenerative surgeryOral health related quality of life will be assessed using the Oral Health Impact Profile-14 (OHIP-14) instrument which assesses quality of life based on 14 questions under the following domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. The scale ranges from 0 to 14 with a higher score indicating a worse outcome.
Proteomic analysis of gingival crevicular fluid (GCF)7, 14 and 30 days after regenerative surgeryProteomic analysis of GCF from the treated teeth using liquid chromatography mass spectrometry (LC-MS) which semi-quantitatively analyses the total number and type (names and IDs) of proteins present in GCF obtained from the test and control sites.

Countries

Norway, Spain

Contacts

CONTACTSiddharth V Shanbhag, Ph.D.
siddhars@uio.no+4740041647
CONTACTAnders Verket, Ph.D.
anderver@odont.uio.no+4722852064
PRINCIPAL_INVESTIGATORSiddharth Shanbhag, Ph.D.

University of Oslo

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026